XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information
 6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has historically reported its activities in two reportable segments; (1) the Clinical Services segment and (2) the Pharma Services segment. In the second quarter of 2023, the Pharma Services segment was rebranded as the Advanced Diagnostics segment.
The financial information reviewed by the CODM includes revenues, cost of revenue, and gross profit for both reportable segments. Assets, operating expenses, loss from operations, and net loss are not presented at the segment level as that information is not used by the CODM. For further details regarding segment reporting, please refer to Note 2. Summary of Significant Accounting Policies.
The following table summarizes the segment information (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Net revenues:
Clinical Services$123,156 $105,635 $238,025 $204,426 
Advanced Diagnostics23,761 19,437 46,112 37,815 
Total revenue146,917 125,072 284,137 242,241 
Cost of revenue:
Clinical Services(1)
71,746 67,035 139,038 132,302 
Advanced Diagnostics(2)
15,280 14,091 30,394 27,761 
Total cost of revenue87,026 81,126 169,432 160,063 
Gross Profit:
Clinical Services51,410 38,600 98,987 72,124 
Advanced Diagnostics8,481 5,346 15,718 10,054 
Total gross profit$59,891 $43,946 $114,705 $82,178 
(1) Clinical Services cost of revenue for both the three months ended June 30, 2023 and June 30, 2022 includes $4.3 million of amortization of acquired Inivata developed technology intangible assets. Clinical Services cost of revenue for both the six months ended June 30, 2023 and June 30, 2022 includes $8.5 million of amortization of acquired Inivata developed technology intangible assets.
(2) Advanced Diagnostics cost of revenue for both the three months ended June 30, 2023 and June 30, 2022 includes $0.6 million of amortization of acquired Inivata developed technology intangible assets. Advanced Diagnostics cost of revenue for both the six months ended June 30, 2023 and June 30, 2022 includes $1.2 million of amortization of acquired Inivata developed technology intangible assets.